ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity.Journal for immunotherapy of cancer · 2026Article
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer.Frontiers in immunology · 2026Review
- Hyper-migratory CAR T cells alleviate ovarian cancer metastatic burden and improve prognosis.bioRxiv : the preprint server for biology · 2025Article
- Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.Molecular cancer · 2025Review
- CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.Immunity, inflammation and disease · 2025Review
- Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma.Genes & diseases · 2025Review
- Long Non-coding RNA FOXD2-AS1 Silencing Inhibits Malignant Behaviors of Ovarian Cancer Cells Via miR-324-3p/SOX4 Signaling Axis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies.Frontiers in immunology · 2025Review
- Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions.Frontiers in immunology · 2025Review
- Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.Cancers · 2024Review
- CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?Diagnostics (Basel, Switzerland) · 2024Review
- Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.Medical oncology (Northwood, London, England) · 2024Review
- Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.Journal for immunotherapy of cancer · 2023Article
- The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer.Current issues in molecular biology · 2023Review
- Review
- Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.Cancer immunology, immunotherapy : CII · 2023Article
- CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.Frontiers in immunology · 2023Review
- The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.Medical oncology (Northwood, London, England) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming growth factor β (TGF-β) receptor family member, overexpressed by most ovarian and endometrial cancers while absent in most normal tissues. Restricted tissue expression, coupled with an understanding that MISIIR ligation transmits apoptotic signals to cancer cells, makes MISIIR an attractive target for tumor-directed therapeutics. However, the development of clinical MISIIR-targeted agents has been challenging. Prompted by the responses achieved in patients with blood malignancies using chimeric antigen receptor (CAR) T cell therapy, we hypothesized that MISIIR targeting may be achieved using a CAR T cell approach. Herein, we describe the development and evaluation of a CAR that targets MISIIR. T cells expressing the MISIIR-specific CAR demonstrated antigen-specific reactivity in vitro and eliminated MISIIR-overexpressing tumors in vivo. MISIIR CAR T cells also recognized a panel of human ovarian and endometrial cancer cell lines, and they lysed a battery of patient-derived tumor specimens in vitro, without mediating cytotoxicity of a panel of normal primary human cells. In conclusion, these results indicate that MISIIR targeting for the treatment of ovarian cancer and other gynecologic malignancies is achievable using CAR technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.